PARP as a Therapeutic Target

edited by Jie Zhang

Features:

• Links the basic PARP pathway to its roles in pathogenesis
• Focuses on the biological activities of PARP inhibition in animal models of diseases
• Presents contributions from leading experts actively conducting PARP research
• Provides perspectives of multiple potentials for the clinical utilities of PARP inhibitors
• Stimulates critical thinking to further push the boundary of our knowledge on PARP, which hopefully will translate into clinical benefits soon

PARP as a Therapeutic Target covers the clinical aspects of this up-and-coming drug that counteracts the damage done by free radicals. Leading international experts currently working on ways to apply it share their views of recent developments and future directions of PARP research. They discuss its therapeutic potential in various disease conditions, such as ischemia, diabetes, cancer, arthritis, inflammatory bowel disease, and septic shock.

This reference provides a comprehensive understanding of how PARP works to aid in the better design of its inhibitors for therapeutic purposes.

Contents

1. Nervous System Functions of Poly(ADP-Ribose) Polymerase-1
2. Role of Poly(ADP-ribose) Polymerase-1 in Neurologic Disorders
3. Involvement of PARP-1 and Poly(ADP-Ribosyl)ation in the Maintenance of Genomic Stability
4. Functional Testing of Human PARP in Proliferation, Endotoxic Shock, and Radiosensitivity: A Genetic Rescue Study
5. PARP Inhibitors as Neuroprotective Agents for Brain Injury
6. PARP Inhibitors and Cardioprotection
7. Neuroprotection of the Retina with 3-Aminobenzamide, a PARP Inhibitor
8. Poly(ADP-ribose) Polymerase Inhibitors and Acute Renal Failure
9. Role of Poly(ADP-ribose) Polymerase Activation in the Pathogenesis of Shock and Inflammation
10. Clinical Development of the Nicotinamides and Benzamides Involving PARP as a Molecular Target
11. Chemoprotective Effect of a Novel PARP Inhibitor
12. Beneficial Effect of GPI 6150 Treatment in Multiple Animal Models of Diseases
13. Protecting Effect of PARP Inhibition on Ultraviolet Light-Induced Skin Damage
14. Role of Poly(ADP-Ribose) Polymerase Activation in the Pathogenesis of Diabetes Mellitus and Diabetic Vascular Dysfunction
15. Therapeutic Targeting of the PARPs: Future Challenges, Future Opportunities

click here to see books • videos • cd-roms of related interest